AbstractObjectivesThe goal of this study was to compare the effects of the vasopeptidase inhibitor omapatrilat and the angiotensin-converting enzyme inhibitor (ACEI) captopril in the postmyocardial infarction (MI) rat model.BackgroundThe cardioprotective effects of ACEIs after MI are thought to be partially due to an increase in bradykinin (BK). Vasopeptidase inhibitors inhibit both ACE and neutral endopeptidase (NEP), further reduce BK metabolism and increase natriuretic peptides, which may result in better cardioprotective effects than with ACEIs after MI.MethodsMyocardial infarction was induced in 514 Wistar male rats by ligation of the anterior coronary artery. Rats surviving 4 h after MI (n = 282) were assigned to omapatrilat (40 or 80...
Background: Captopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treat...
Microvascular remodeling contributes to increased cardio-vascular risk in hypertension. The dual ang...
Background: Clinical trials in heart failure have focused on the improvement in symptoms or decrease...
AbstractObjectivesThe goal of this study was to compare the effects of the vasopeptidase inhibitor o...
AbstractObjectives. This study sought to compare the effects of angiotension-converting enzyme inhib...
Abstract: Background and objective: Angiotensin-converting enzyme (ACE) inhibitors have been reporte...
Angiotensin I converting enzyme (ACE) inhibitors are widely used in the treatment of heart failure. ...
During the last 25 years angiotensin-converting enzyme inhibitors spectacularly conquered the field ...
To evaluate the mechanisms and the impact of the ACE-inhibitor perindopril (P) in a model of doxorub...
To compare the effects of angiotensin converting enzyme (ACE) inhibition vs angiotensin II (A-II) re...
AbstractObjectivesWe investigated the acute and long-term hemodynamic and neurohumoral effects of th...
Inhibition of tissue angiotensin-converting-enzyme (ACE) activity can potentially block both myocyte...
Objective – Angiotensin-converting enzyme inhibi-tors (ACEIs) have gained importance in preventing o...
Omapatrilat, a vasopeptidase inhibitor, inhibits both neutral endopeptidase and angiotensin-converti...
AbstractOBJECTIVESThe purpose of this study was to explore interactions between paracrine angiotensi...
Background: Captopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treat...
Microvascular remodeling contributes to increased cardio-vascular risk in hypertension. The dual ang...
Background: Clinical trials in heart failure have focused on the improvement in symptoms or decrease...
AbstractObjectivesThe goal of this study was to compare the effects of the vasopeptidase inhibitor o...
AbstractObjectives. This study sought to compare the effects of angiotension-converting enzyme inhib...
Abstract: Background and objective: Angiotensin-converting enzyme (ACE) inhibitors have been reporte...
Angiotensin I converting enzyme (ACE) inhibitors are widely used in the treatment of heart failure. ...
During the last 25 years angiotensin-converting enzyme inhibitors spectacularly conquered the field ...
To evaluate the mechanisms and the impact of the ACE-inhibitor perindopril (P) in a model of doxorub...
To compare the effects of angiotensin converting enzyme (ACE) inhibition vs angiotensin II (A-II) re...
AbstractObjectivesWe investigated the acute and long-term hemodynamic and neurohumoral effects of th...
Inhibition of tissue angiotensin-converting-enzyme (ACE) activity can potentially block both myocyte...
Objective – Angiotensin-converting enzyme inhibi-tors (ACEIs) have gained importance in preventing o...
Omapatrilat, a vasopeptidase inhibitor, inhibits both neutral endopeptidase and angiotensin-converti...
AbstractOBJECTIVESThe purpose of this study was to explore interactions between paracrine angiotensi...
Background: Captopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treat...
Microvascular remodeling contributes to increased cardio-vascular risk in hypertension. The dual ang...
Background: Clinical trials in heart failure have focused on the improvement in symptoms or decrease...